Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs Platform will ...
Recursion Pharmaceuticals is merging with Exscientia. The new entity will have the backing of quite a few big names in pharma. It'll also have an even more capable drug discovery and development ...
Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug ...
I'm about 98% done building an app for parsing a certain network vendor's XML dumps, and need some help with group objects I know I should have used etree, but minidom seemed too straight forward to ...
Recursion is using AI and machine learning to accelerate drug research and development. The stock has been under pressure amid an uncertain near-term financial outlook. Several clinical updates from ...
June 10 (Reuters) - Recursion Pharmaceuticals (RXRX.O), opens new tab said on Tuesday it would lay off about 20% of its workforce as the biotech company tries to cope with an industry-wide funding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback